BD reports prelim Q4 rev $5.9B (+8.3%); CFO DelOrefice to depart Dec 5; Roque interim CFO

BECTON DICKINSON & CO

2025-FY EPS reported $5.82 vs consensus $2.84 ▲ beat (+104.9%)

Preliminary Q4 revenue ~$5.9B, up 8.3% reported, 3.9% organic; FY revenue ~$21.8B, up 8.2% reported, 2.9% organic.
CFO Chris DelOrefice resigns effective Dec 5, 2025 to pursue new opportunity; departure not due to disagreement.
Vitor Roque, SVP Finance, named interim CFO effective upon DelOrefice's departure; permanent search underway.
FY2025 adjusted diluted EPS expected at or above midpoint of prior guidance.
Headwinds in Pharma Systems vaccines and Biosciences academic/govt research; strong growth in Interventional, APM, Med Delivery Solutions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.